Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Baird Maintains Outperform on Apellis Pharmaceuticals, Raises Price Target to $105

Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and raises the price target from $90 to $105.
byBenzinga Newsdesk
February 21, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and raises the price target from $90 to $105.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts